Drug Profile

IDE 892

Alternative Names: IDE-892

Latest Information Update: 21 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IDEAYA Biosciences
Class Antineoplastics
Mechanism of Action PRMT5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

13 Feb 2025 IDEAYA Biosciences plans to initiate a clinical trial for Non-small cell lung cancer and Urogenital cancer (Combination therapy), in the second half of 2025
09 Dec 2024 Preclinical trials in Solid tumours in USA
09 Dec 2024 IDEAYA Biosciences plans to submit an Investigational New Drug (IND) filing to the US FDA in mid-2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com